TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer

Cancer Research

Volumn 74, Issue 18, 2014, Pages 5008-5018

  Chatterjee, Saradiya ^a,b,c   Crozet, Lucile ^a,b,c   Damotte, Diane ^a,b,c,d   Iribarren, Kristina ^a,b,c   Schramm, Catherine ^a,b,c   Alifano, Marco ^d   Lupo, Audrey ^a,c,d   Cherfils Vicini, Julien ^a,b,c   Goc, Jeremy ^a,b,c   Katsahian, Sandrine ^a,b,c   Younes, Mohammad ^d   Dieu Nosjean, Marie Caroline ^a,b,c   Fridman, Wolf Herman ^a,b,c   Sautès Fridman, Catherine ^a,b,c   Cremer, Isabelle ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE; LOXORIBINE; MEMBRANE PROTEIN; TLR7 PROTEIN, HUMAN; TLR7 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 7;

AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; FEMALE; HUMAN; LUNG NEOPLASMS; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GUANOSINE; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 7;

EID: 84907499681     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2698     Document Type: Article

References (39)

1. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventhhallmarkof cancer: links togenetic instability. Carcinogenesis 2009;30:1073-81.
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
3. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76.
4. Yu L, Wang L, Chen S. Dualcharacter of Toll-like receptorsignaling: protumorigenic effects and anti-tumor functions. Biochim Biophys Acta 2013;1835:144-54.
5. Adams S. Toll-like receptoragonists in cancer therapy. Immunotherapy 2009;1:949-64.
6. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012;1:699-716.
7. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012;1:894-907.
8. Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010;120:1285-97.
9. Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B. Tolllike receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res 2005;6:68.
10. He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007;44:2850-9.
11. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65:5009-14.
12. Huang B, Zhao J, Shen S, Li H, He KL, Shen GX, et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 2007;67:4346-52.
13. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006;176:4894-901.
14. Sato Y, Goto Y, Narita N, Hoon DS. Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron 2009;2:205-14.
15. Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 2012;22:466-78.
16. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006;66:3859-68.
17. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, et al. Triggering of Toll-like receptor4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009;69:3105-13.
18. Sautes-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, et al. Tumor microenvironmentismultifaceted. Cancer Metastasis Rev 2011;30:13-25.
19. Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C, et al. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med 2010;8:112.
20. Zhu Y, Huang JM, Zhang GN, Zha X, Deng BF. Prognostic significance of MyD88 expression by human epithelialovarian carcinoma cells. J Transl Med 2012;10:77.
21. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Globalcancer statistics. CA Cancer J Clin 2011;61:69-90.
22. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011;71:3-10.
23. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell 2011;19:11-5.
24. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012;31:1869-83.
25. Chung LY, Tang SJ, Sun GH, Chou TY, Yeh TS, Yu SL, et al. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res 2012;18:4037-47.
26. Guo J, Kim D, Gao J, Kurtyka C, Chen H, Yu C, et al. IKBKEisinducedby STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene 2013;32:151-9.
27. Ardies CM. Inflammation as cause for scar cancers of the lung. Integr Cancer Ther 2003;2:238-46.
28. Brenner DR, McLaughlin JR, Hung RJ. Previouslung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS ONE 2011;6:e17479.
29. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008;26:4410-7.
30. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;136:260-71.
31. Brambilla E, Travis WD, Colby TV, Corrin B, ShimosatoY. ThenewWorld Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-68.
32. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-35.
33. Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005;202:1131-9.
34. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007;18:1721-31.
35. Ochi A, Graffeo CS, Zambirinis CP, Rehman A, Hackman M, Fallon N, et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest 2012;122:4118-29.
36. Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu HH, et al. MyD88 predictschemoresistance topaclitaxel in epithelialovarian cancer. Yale J Biol Med 2006;79:153-63.
37. Gantier MP, Tong S, Behlke MA, Xu D, Phipps S, Foster PS, et al. TLR7 is involved in sequence-specific sensing of single-stranded RNAs in human macrophages. J Immunol 2008;180:2117-24.
38. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 2012;109:E2110-6.
39. Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 2012;9:144-55.